Skip to content

Lori Anne Kunkel, Director at Enliven Therapeutics, sold ELVN on Jul 6, 2026

Data as of Oct 16

▼ SELL$205K4,111 shares at $49.98Lori Anne Kunkel DirectorELVN Enliven Therapeutics, Inc.
Watch ELVN
Traded
Jul 6, 2026
Disclosed
Jul 8, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Lori Anne Kunkel, Director at Enliven Therapeutics, sold ELVN on Jul 6, 2026TRADEDDISCLOSED
ELVNSimilar stocks (XLV — its sector index fund), rebased to ELVN's price on the disclosure day
ELVN since disclosure
−26.5%
after the sale
Similar stocks (XLV) since disclosure
+8.9%
XLV — its sector index fund

Change in closing price from Jul 8, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLLori Anne Kunkel DirectorELVN Enliven Therapeutics, Inc.$299Kdisclosed Jul 8 · filed 2 days after the trade

See every trade on ELVN →